Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells

Published:2010-08 Issue:8 Volume:5 Page:1143-1151
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Wu Ming-Fang,Hsiao Yi-Min,Huang Chuan-Fu,Huang Yu-Hsin,Yang Wan-Jung,Chan Hsiu-Wen,Chang Jinghua Tsai,Ko Jiunn-Liang

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Emerging drugs for mesothelioma;Scagliotti;Expert Opin Emerg Drugs,2007

2. Role of pemetrexed in non-small cell lung cancer;Longo-Sorbello;Cancer Invest,2007

3. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

4. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis;Ramirez;Leukemia,2007

5. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line;Wang;Biochem Pharmacol,2003

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of molecular subtypes in lung adenocarcinoma based on DNA methylation and gene expression profiling—a bioinformatic analysis;Annals of Translational Medicine;2022-08

2. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers;Nature Communications;2022-04-04

3. Molecular profiles of predictive biomarkers for platinum-based chemotherapy in Non-Small Cell Lung Cancer (NSCLC);Meta Gene;2022-02

4. Antifolate-based anticancer drugs;New Strategies Targeting Cancer Metabolism;2022

5. Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer;Cancer Management and Research;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3